A Study of Inhaled AZD8630 in Adolescents with Asthma - APkITA
Study identifier:D6830C00005
ClinicalTrials.gov identifier:NCT07065331
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
A Phase I, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Inhaled AZD8630 in Adolescents with Asthma
Medical condition
asthma
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD8630
Sex
All
Estimated Enrollment
19
Study type
Interventional
Age
12 Years - 17 Years
Date
Study Start Date: 11 Jun 2025
Estimated Primary Completion Date: 25 Feb 2026
Estimated Study Completion Date: 25 Feb 2026
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2025 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Other
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD8630 Participants will receive single inhaled dose of AZD8630 on Day 1 via dry powder inhaler. | - |
